US Price Negotiation Process: Is Case-By-Case Politically Sustainable?
Republican Congressional letter asking HHS nuts-and-bolts questions about the newly enacted drug price ‘negotiation’ law points to a much more fundamental issue: can a bureaucratic agency make the program work in a manner that appears credible and free of undue political interference?
You may also be interested in...
Offering a glimpse of what to expect if the GOP wins the House in the midterm elections, Reps. McMorris Rodgers and Brady urge transparency from HHS, ask lots of questions, and request monthly briefings on plans for implementation.
With enactment of the drug pricing reform provisions in the Inflation Reduction Act, stakeholders now turn their attention to the implementing regulations that will be developed by the Centers for Medicare and Medicaid Services.
Heavily rebated drugs may already be meeting the price goals established by the Senate legislation. As a result, price negotiation for drugs covered under Part B are likely to yield greater savings to the Medicare program than Part D.